OPIANT PHARMACEUTICALS, INC. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2010 to Q3 2022

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Opiant Pharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q3 2010 to Q3 2022.
  • Opiant Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2022 was -$9.92M, a 390% decline year-over-year.
  • Opiant Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending September 30, 2022 was -$33.1M, a 2206% decline year-over-year.
  • Opiant Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was $3.01M.
  • Opiant Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$1.86M, a 116% decline from 2019.
  • Opiant Pharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2019 was $11.6M.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2022 -$33.1M -$9.92M -$13.3M -390% Jul 1, 2022 Sep 30, 2022 10-Q 2022-11-14
Q2 2022 -$19.8M -$11.7M -$13.4M -797% Apr 1, 2022 Jun 30, 2022 10-Q 2022-11-14
Q1 2022 -$6.33M -$12.2M -$9.34M -329% Jan 1, 2022 Mar 31, 2022 10-Q 2022-11-14
Q4 2021 $3.01M $752K +$1.44M Oct 1, 2021 Dec 31, 2021 10-K 2022-03-15
Q3 2021 $1.57M $3.42M +$2.69M +371% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$1.12M $1.68M +$1.9M Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-14
Q1 2021 -$3.02M -$2.84M -$1.16M -68.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-14
Q4 2020 -$1.86M -$686K -$1.75M -164% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-15
Q3 2020 -$108K $725K -$9.96M -93.2% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 $9.85M -$216K -$1.79M -114% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-12
Q1 2020 $11.6M -$1.68M +$51.4K +2.96% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-12
Q4 2019 $11.6M $1.07M +$10.6M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-04
Q3 2019 $988K $10.7M +$11.6M Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 -$10.6M $1.58M +$2.98M Apr 1, 2019 Jun 30, 2019 10-Q 2020-11-12
Q1 2019 -$13.6M -$1.74M +$7.61M +81.4% Jan 1, 2019 Mar 31, 2019 10-Q 2020-11-12
Q4 2018 -$21.2M -$9.54M -$12.9M -384% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-04
Q3 2018 -$8.3M -$918K +$2.49M +73.1% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 -$10.8M -$1.4M -$1.64M -685% Apr 1, 2018 Jun 30, 2018 10-Q 2019-11-12
Q1 2018 -$9.15M -$9.34M -$6.55M -234% Jan 1, 2018 Mar 31, 2018 10-Q 2019-11-12
Q4 2017 -$2.61M $3.36M -$7.29M -68.4% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-21
Q3 2017 $4.68M -$3.41M -$2.81M -467% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $7.49M $239K +$1.33M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $6.16M -$2.8M -$3.21M -772% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q4 2016 $9.37M $10.6M +$6.68M +168% Nov 1, 2016 Jan 31, 2017 10-Q 2017-03-15
Q3 2016 $2.69M -$601K +$10.5M +94.6% Aug 1, 2016 Oct 31, 2016 10-Q 2017-12-04
Q2 2016 -$7.81M -$1.09M +$546K +33.4% May 1, 2016 Jul 31, 2016 10-KT 2018-03-07
Q1 2016 -$8.36M $416K +$2.27M Feb 1, 2016 Apr 30, 2016 10-Q 2017-06-14
Q4 2015 -$10.6M $3.97M +$6.75M Nov 1, 2015 Jan 31, 2016 10-Q 2017-03-15
Q3 2015 -$17.4M -$11.1M -$10.3M -1333% Aug 1, 2015 Oct 31, 2015 10-Q 2016-12-15
Q2 2015 -$7.04M -$1.64M +$2.52M +60.7% May 1, 2015 Jul 31, 2015 10-K 2016-10-28
Q1 2015 -$9.56M -$1.85M -$1.3M -234% Feb 1, 2015 Apr 30, 2015 10-Q 2016-06-08
Q4 2014 -$8.26M -$2.78M +$2.28M +45.1% Nov 1, 2014 Jan 31, 2015 10-Q 2016-03-15
Q3 2014 -$10.5M -$775K +$938K +54.8% Aug 1, 2014 Oct 31, 2014 10-Q 2015-12-14
Q2 2014 -$11.5M -$4.16M -$2.89M -227% May 1, 2014 Jul 31, 2014 10-K 2015-10-26
Q1 2014 -$8.6M -$554K +$203K +26.8% Feb 1, 2014 Apr 30, 2014 10-Q 2015-06-12
Q4 2013 -$8.8M -$5.06M +$1.24M +19.6% Nov 1, 2013 Jan 31, 2014 10-Q 2015-03-17
Q3 2013 -$10M -$1.71M -$857K -99.9% Aug 1, 2013 Oct 31, 2013 10-Q 2014-12-09
Q2 2013 -$9.18M -$1.27M +$378K +22.9% May 1, 2013 Jul 31, 2013 10-K 2014-10-27
Q1 2013 -$9.56M -$757K +$716K +48.6% Feb 1, 2013 Apr 30, 2013 10-Q 2014-06-10
Q4 2012 -$10.3M -$6.29M -$1.71M -37.4% Nov 1, 2012 Jan 31, 2013 10-Q 2014-03-17
Q3 2012 -$8.56M -$857K +$3.86M +81.8% Aug 1, 2012 Oct 31, 2012 10-Q 2013-12-16
Q2 2012 -$12.4M -$1.65M +$1.11M +40.2% May 1, 2012 Jul 31, 2012 10-K 2013-10-29
Q1 2012 -$13.5M -$1.47M +$3.93M +72.7% Feb 1, 2012 Apr 30, 2012 10-Q 2013-06-14
Q4 2011 -$17.5M -$4.58M -$3.58M -360% Nov 1, 2011 Jan 31, 2012 10-Q 2013-03-18
Q3 2011 -$13.9M -$4.72M -$4.44M -1575% Aug 1, 2011 Oct 31, 2011 10-Q 2012-12-20
Q2 2011 -$9.44M -$2.76M May 1, 2011 Jul 31, 2011 10-Q 2012-12-20
Q1 2011 -$5.4M Feb 1, 2011 Apr 30, 2011 10-Q 2012-06-14
Q4 2010 -$995K Nov 1, 2010 Jan 31, 2011 10-Q 2012-03-16
Q3 2010 -$282K Aug 1, 2010 Oct 31, 2010 10-Q 2011-12-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.